Whanin Pharm KRX:016580KOSPI
환인제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days2
DART filings, 7 days1
Articles tracked3since Sep 11
In Q2 2026, Whanin Pharm reported revenue of ₩71.4bn, up 11.4% year on year, and operating profit of ₩7.9bn. Whanin Pharm (환인제약) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 30 with 2 articles. The most common catalyst was earnings (1).
Filing signals Profit +50% Revenue & profit growth Screener
Whanin Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩71.4bn | +11.4% | ₩7.9bn margin 11.1% | ₩7.7bn |
| Q1 2026 | ₩71.2bn | +18.2% | ₩9.4bn margin 13.2% | ₩7.5bn |
| Q4 2025 derived | ₩65.1bn | -1.7% | ₩1.5bn margin 2.3% | ₩2.0bn |
| Q3 2025 | ₩65.7bn | -3.5% | ₩3.6bn margin 5.4% | ₩3.3bn |
| Q2 2025 | ₩64.1bn | +0.8% | ₩2.7bn margin 4.2% | ₩3.2bn |
| Q1 2025 | ₩60.2bn | -2.3% | ₩5.3bn margin 8.8% | ₩5.1bn |
| Q4 2024 derived | ₩66.3bn | +13.5% | ₩913m margin 1.4% | ₩3.6bn |
| Q3 2024 | ₩68.1bn | +15.8% | ₩5.3bn margin 7.8% | ₩4.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Whanin Pharm top stories 2 weeks, by number of outlets
- 1
- 2